Highest-materiality recent filing
Sarepta Q1 GAAP EPS $2.88 vs loss of $4.60; siRNA pipeline shows early positive data
Net product revenue $330.5M (ELEVIDYS $102.0M, PMO $228.6M); total rev $730.8M (-2% YoY).
Sarepta reports Q4 2025 net loss of $412.2M; full-year revenue up 16% to $2.2B
Full-year 2025 net product revenue $1,864.3M (PMO $965.6M, ELEVIDYS $898.7M); Q4 net product revenue $369.6M.
Sarepta CEO Douglas Ingram to retire by end of 2026; successor search underway
CEO Douglas Ingram notified retirement by end of 2026 or upon appointment of replacement.
Sarepta preliminary 2025 net product revenue $1.86B; ELEVIDYS $898.7M
Total net product revenue Q4 $369.6M, full-year $1.86B; cash and investments $953.8M at year-end.
Sarepta exchanges $291.4M of 1.25% notes for 4.875% notes due 2030 plus $31.6M cash
Exchanged ~$291.4M of existing 1.25% Convertible Senior Notes due 2027 for new 4.875% Convertible Notes due 2030 plus ~$31.6M cash.
Sarepta exchanges $291M of 1.25% notes due 2027 for 4.875% notes due 2030 plus $31.6M cash
Exchanges $291.4M principal of 1.25% convertibles due 2027 for same principal of 4.875% convertibles due 2030, plus $31.6M in cash.
Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint
ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).
Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash
Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.
Sarepta exchanges $700M of 1.25% notes due 2027 for new 4.875% notes due 2030, stock, and cash
Exchanged ~$700M existing 1.25% convertible notes for $602M new 4.875% notes due 2030, $110M stock, and ~$123.3M cash.
FDA places clinical hold on Sarepta's LGMD gene therapy trials; revokes AAVrh74 platform designation
FDA placed clinical hold on LGMD trials for SRP-9003, SRP-9004, SRP-6004, and SRP-9005.
Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning
Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.
Sarepta Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS $384.2M; GAAP net income $159M
Q4 net product revenue $638.2M (+75% YoY); ELEVIDYS contributed $384.2M; royalty from Roche $4.9M.
Sarepta enters $600M senior secured revolving credit facility with JPMorgan as admin agent
Five-year $600M revolving credit facility closed Feb 13, 2025; variable interest at Adjusted SOFR + 1.125%-1.75% spread based on leverage.
Preliminary total net product revenue Q4 2024 $638.2M, FY2024 $1.79B, exceeding full-year guidance by over $100M.
Sarepta enters $500M upfront license deal with Arrowhead for siRNA therapies; GC resigns
$500M upfront cash to Arrowhead; up to $300M near-term payments; up to $180M per program development milestones, $700M per program sales milestones; tiered royalties up to low double digits.
Ryan Brown informed Sarepta of his resignation from his position as the Company’s Executive Vice President, Chief General Counsel, effective as of November 26, 2024.
Cristin Rothfuss, the Company’s Senior Vice President, Deputy General Counsel, will succeed Mr. Brown as the Company’s Executive Vice President, General Counsel.
On September 12, 2024, the board of directors (the “ Board ”) of Sarepta Therapeutics, Inc. (the “ Company ”) appointed Deirdre Connelly as a director of the Company, effective immediately, to serve as a member of Class I until the 2026 annual meeting of stockholders.
Max materiality 0.90 · Median 0.70 · Most common event earnings